方盛制药(603998) - 2025 Q2 - 季度财报

Important Notice This section provides critical disclaimers and affirmations regarding the semi-annual report's accuracy and the company's operational status. I. Board of Directors and Senior Management Statement The Board of Directors and senior management affirm the semi-annual report's truthfulness, accuracy, and completeness, assuming legal responsibility - The Board of Directors and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report[5] - Company head Zhou Xiaoli, chief accountant Cao Xiangqi, and accounting department head Cao Xiangqi affirm the financial report's truthfulness, accuracy, and completeness[6] II. Board Meeting Attendance All company directors attended the Board of Directors meeting - All company directors attended the Board of Directors meeting[5] III. Report Audit Status This semi-annual report is unaudited - This semi-annual report is unaudited[5] V. Profit Distribution Plan The Board approved a profit distribution plan of 1.50 yuan (tax inclusive) cash dividend per 10 shares to all registered shareholders, with no bonus shares or capital reserve conversions - The Board approved a 1.50 yuan (tax inclusive) cash dividend per 10 shares to all registered shareholders based on the total share capital on the equity registration date for profit distribution[6] - No bonus shares or capital reserve conversions[6] VI. Forward-Looking Statements Risk Disclaimer Forward-looking statements regarding future plans and strategies do not constitute a substantial commitment to investors, urging caution on investment risks - Forward-looking statements regarding future plans and development strategies in this report do not constitute a substantial commitment to investors[7] - Investors are advised to be aware of investment risks[7] VII. Controlling Shareholder and Related Party Fund Occupation There is no non-operating occupation of funds by controlling shareholders or other related parties - No non-operating occupation of funds by controlling shareholders or other related parties[8] VIII. External Guarantees The company has not provided external guarantees in violation of prescribed decision-making procedures - No external guarantees were provided in violation of prescribed decision-making procedures[8] IX. Directors' Assurance of Report Authenticity No more than half of the directors are unable to guarantee the truthfulness, accuracy, and completeness of the semi-annual report - No more than half of the directors are unable to guarantee the truthfulness, accuracy, and completeness of the company's semi-annual report[8] X. Significant Risk Alerts No particularly significant risks substantially affecting operations were identified during the reporting period; detailed risks are in the 'Potential Risks' section of Management Discussion and Analysis - No particularly significant risks substantially affecting the company's operations were identified during the reporting period[8] - The company has detailed various risks in its operations in this report, see "Potential Risks" in "Section III Management Discussion and Analysis"[8] Section I Definitions This section provides a glossary of common terms used throughout the report, including company and subsidiary names, industry jargon, and regulatory bodies Definitions of Common Terms This section defines common terms, including company and subsidiary names, industry jargon (e.g., GMP, OTC, innovative traditional Chinese medicine), and regulatory bodies, providing a basis for understanding the report - Glossary of common terms, including names of subsidiaries such as the Company, Lühe Pharmaceutical, Fangsheng Jianmeng, and Fuya Bio[14] - Explanation of industry terms such as GMP (Good Manufacturing Practice), OTC (Over-the-Counter drugs), and innovative traditional Chinese medicine[15] - Lists regulatory bodies including MIIT, National Healthcare Security Administration, National Health Commission, CSRC, SSE, and NMPA[15] Section II Company Profile and Key Financial Indicators This section provides an overview of the company's basic information and presents its key financial performance metrics I. Company Information This section provides basic registration information, including the company's Chinese name, abbreviation, foreign name, and legal representative - The company's Chinese name is Hunan Fangsheng Pharmaceutical Co., Ltd., abbreviated as Fangsheng Pharmaceutical[17] - The company's legal representative is Zhou Xiaoli[17] II. Contact Persons and Contact Information This section lists the names, contact addresses, phone numbers, fax numbers, and email addresses of the Board Secretary and Securities Affairs Representative - The Board Secretary is He Shi, and the Securities Affairs Representative is Wang Chaoxia[18] - Contact phone number is 0731-88997135, and email addresses are heshi001@fangsheng.com.cn and wangchaoxia@fangsheng.com.cn respectively[18] III. Brief Introduction to Changes in Basic Information This section details the company's registered and office addresses, noting no changes during the reporting period - The company's registered address is No. 789 Lusong Road, High-tech Zone, Changsha, and its office address is No. 299 Jiayun Road, National High-tech Industrial Development Zone, Changsha[19] - No changes to the company's registered or office addresses during the reporting period[19] IV. Brief Introduction to Changes in Information Disclosure and Document Storage Locations This section discloses the designated newspapers for information disclosure, the website address for the semi-annual report, and the report's storage location, with no changes during the reporting period - The company's designated information disclosure newspapers are China Securities Journal, Shanghai Securities News, Securities Times, and Securities Daily[20] - The website address for the semi-annual report is www.sse.com.cn[20](index=20&type=chunk) - The company's semi-annual report is available at No. 299 Jiayun Road, National High-tech Industrial Development Zone, Changsha, with no changes during the reporting period[20] V. Company Stock Overview This section provides the company's stock type, listing exchange, stock abbreviation, and stock code - The company's stock type is A-shares, listed on the Shanghai Stock Exchange[21] - Stock abbreviation is Fangsheng Pharmaceutical, stock code is 603998[21] VII. Company Key Accounting Data and Financial Indicators This section details key accounting data and financial indicators for H1 2025 versus prior year, explaining revenue decline alongside improved profitability H1 2025 Key Accounting Data vs. Prior Period | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 834.25 million yuan | 910.25 million yuan | -8.35 | | Total Profit | 186.49 million yuan | 155.20 million yuan | 20.16 | | Net Profit Attributable to Shareholders | 169.24 million yuan | 136.84 million yuan | 23.67 | | Net Profit Attributable to Shareholders After Non-Recurring Gains/Losses | 141.47 million yuan | 110.71 million yuan | 27.79 | | Net Cash Flow from Operating Activities | 129.49 million yuan | 66.34 million yuan | 95.19 | | Net Assets Attributable to Shareholders (Period-End) | 1.639 billion yuan | 1.511 billion yuan | 8.43 | | Total Assets (Period-End) | 3.057 billion yuan | 3.227 billion yuan | -5.29 | H1 2025 Key Financial Indicators vs. Prior Period | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic EPS (yuan/share) | 0.39 | 0.32 | 21.88 | | Diluted EPS (yuan/share) | 0.